- POSITIVE
Quarterly Revenue Sahajanand Medical Sep-2026 Quarterly Revenue is Rs 161 Cr which is growth of 17.4% YoY.
- NEGATIVE
Quarterly Net Profit Sahajanand Medical Sep-2026 Quarterly Net Profit is Rs 10 Cr which is growth of -19.5% YoY.
NSE: SMT | BSE: 545001|ASM
Sahajanand Medical Live Share Price Today, Share Analysis and Chart
aboutSahajanand Medical Technologies was incorporated on September 30, 2001. The company is an R&D-driven; developer of Class III and Class C/D medical devices, focused on Vascular Intervention and Structural Heart solutions. Its portfolio includes corona... Read More
527.60-11.45(-2.12%)
488.7K
NSE+BSE Volume
NSE 20 Nov, 2026 3:31 PM
Check Before You Buy
Medium rank
4Positive6Negative
40.0%Pass in checklist
Check P/E Buy Sell Zone
Not enough data available
Sahajanand Medical Stock Price Ranges
Day Price Range-2.1% 1 Day return | 527.6 (LTP) 519537 LowHigh |
|---|---|
Week Price Range4.6% 1 Week return | 527.6 (LTP) 492578.7 LowHigh |
Month Price Range53.4% 1 Month return | 527.6 (LTP) 346.6578.7 LowHigh |
52 Week Price Range53.4% 1 Year return | 527.6 (LTP) 346.6578.7 LowHigh |
Peers
Quarterly
Annual
Balance Sheet
Ratios
Cash Flow
Documents
Sahajanand Medical quarterly results: revenue, profit, and P&L – 13 quarter history
Nested row level
Base Level
Reporting Type
Standalone
Cell Data
Actual
Table Settings
YoY & New to Old
Nested row level
Base Level
Export
| Indicator | Graph | Sep '26 | Jun '26 | Sep '25 | Jun '25 |
|---|---|---|---|---|---|
| 160.5 | 154.8 | 136.7 | 125.2 | ||
Operating Exp. | 138.2 | 132.9 | 111.6 | 115.3 | |
Operating Profit | 20.4 | 20.5 | 23.4 | 8.2 | |
Operating Profit Margin % | 12.87% | 13.37% | 17.34% | 6.61% | |
Depr. | 5.1 | 4.7 | 5.1 | 4.6 | |
Interest | 4.2 | 4.2 | 4.7 | 3.8 | |
Profit Before Tax | 13.1 | 13 | 15.4 | 1.5 | |
Tax | 3.2 | 3.7 | 3.2 | -8.2 | |
Net Profit | 9.8 | 9.3 | 12.2 | 9.6 | |
EPS Adj. latest | 1 | 0.9 | 1.2 | 1 | |
Net profit TTM | - | - | - | - | |
Basic EPS TTM | - | - | - | - | |
Earnings Transcripts | |||||
Results PDF | |||||
Result Notes |
*All financials are in INR Cr and price data in INR
Add metric to table
Search...
Sahajanand Medical Technical Analysis
Sahajanand Medical EMA & SMA
Bullish+2
Bullish3
Bearish1
| 5 Day | 534.1 |
|---|---|
| 10 Day | 524.2 |
| 12 Day | 518 |
|---|---|
| 20 Day | 495.9 |
Sahajanand Medical Delivery And Volume
Daily Avg. Delivery Volume %
20 Nov, 202644.3%
Week33.7%
Month25.4%
Sahajanand Medical Active Candlesticks
Hikkake Uptrend
PositiveNeutralNegative
Sahajanand Medical Resistance and Support
527.87
Pivot
| First Resistance | 536.7 |
|---|---|
| Second Resistance | 545.9 |
| Third Resistance | 554.7 |
| First Support | 518.7 |
|---|---|
| Second Support | 509.9 |
| Third Support | 500.7 |
| Day RSI | 69.5 |
|---|---|
| Day MACD | - |
| Day MFI | 75.5 |
| Day MACD Signal Line | - |
Sahajanand Medical Beta
| 1 Month | - |
|---|---|
| 1 Year | - |
| 3 Month | - |
|---|---|
| 3 Year | - |
Sahajanand Medical Price Change Analysis
↑53.4%
Over 1 Month
LowHigh
346.7578.7
↑53.4%
Over 3 Months
LowHigh
346.7578.7
↑53.4%
Over 6 Months
LowHigh
346.7578.7
↑53.4%
Over 1 Year
LowHigh
346.7578.7
Sahajanand Medical Deals - Insider, Bulk, Block and SAST
| Client Name | Deal Type | Action | Date | Avg. Price | Quantity | Exchange |
|---|---|---|---|---|---|---|
| JUMP TRADING FINANCIAL INDIA PRIVATE LIMITED | Bulk | Sell | 28 Oct 2026 | 508.54 | 555,833 | NSE |
| MICROCURVES TRADING PRIVATE LIMITED | Bulk | Sell | 28 Oct 2026 | 502.01 | 575,186 | NSE |
| ALPHAGREP SECURITIES PRIVATE LIMITED | Bulk | Sell | 28 Oct 2026 | 508.15 | 719,743 | NSE |
| JUMP TRADING FINANCIAL INDIA PRIVATE LIMITED | Bulk | Purchase | 28 Oct 2026 | 515.65 | 569,867 | NSE |
| MICROCURVES TRADING PRIVATE LIMITED | Bulk | Purchase | 28 Oct 2026 | 501.64 | 575,186 | NSE |
| ALPHAGREP SECURITIES PRIVATE LIMITED | Bulk | Purchase | 28 Oct 2026 | 509.43 | 719,743 | NSE |
| GRT STRATEGIC VENTURES LLP | Bulk | Sell | 23 Oct 2026 | 382.54 | 538,038 | NSE |
| GRT STRATEGIC VENTURES LLP | Bulk | Purchase | 23 Oct 2026 | 382.37 | 538,038 | NSE |
| INVESCO MUTUAL FUND | Bulk | Purchase | 23 Oct 2026 | 371.44 | 2,807,366 | NSE |
| INVESCO MUTUAL FUND | Bulk | Purchase | 23 Oct 2026 | 374.91 | 800,000 | NSE |
Sahajanand Medical Corporate Actions
Sahajanand Medical Board Meetings
Sahajanand Medical past and upcoming board meetings.
#Ex-Date | Purpose | Notes |
|---|---|---|
105 Nov 2026 | Quarterly Results | - |
Sahajanand Medical Research Reports
Sahajanand Medical research reports with share price targets, and buy/hold/sell recommendations from top brokers.
Sahajanand Medical Corporate Filings
Sahajanand Medical BSE corporate filings and AGM, press releases, insider trading & SAST, results and corporate actions.
| Date | Announcement Title | Details | Links |
|---|---|---|---|
| 20 Nov 2026 | Sahajanand Medical Technologies Ltd - 545001 - Intimation Under Regulation 7(1) Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015 | Appointment of MUFG Intime India Private Limited as the Registrar & Share Transfer Agent of the Company w.e.f. October 23, 2026 (Date of Listing) | |
| 10 Nov 2026 | Sahajanand Medical Technologies Ltd - 545001 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | Schedule of Analyst/Investor Meet | |
| 08 Nov 2026 | Sahajanand Medical Technologies Ltd - 545001 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript | Transcript of Earnings Call for Q2 & H1 FY27 Financial Results held on Thursday, November 05, 2026. | |
| 06 Nov 2026 | Q2FY27 Quarterly Result Announced for Sahajanand Medical Technologies Ltd. | Healthcare Facilities company Sahajanand Medical Technologies announced Q2FY27 results Consolidated Financial Highlights: Revenue from Operations: Stood at Rs 37,341.01 lakh in Q2FY27, growing 6.18% QoQ from Rs 35,166.85 lakh in Q1FY27 and increasing 24.69% YoY compared to Rs 29,947.09 lakh in Q2FY26. Other Income: Reported at Rs 223.58 lakh in Q2FY27, declining 16.04% QoQ from Rs 266.30 lakh in Q1FY27 and down 4.59% YoY compared to Rs 234.33 lakh in Q2FY26. Total Income: Stood at Rs 37,564.59 lakh in Q2FY27, reflecting an increase of 6.02% QoQ compared to Rs 35,433.15 lakh in Q1FY27 and a growth of 24.46% YoY from Rs 30,181.42 lakh in Q2FY26. Profit Before Tax (PBT): Rose to Rs 4,006.87 lakh in Q2FY27, up 64.99% QoQ from Rs 2,428.52 lakh in Q1FY27 and higher by 47.92% YoY compared to Rs 2,708.77 lakh in Q2FY26. Profit After Tax (PAT): Reached Rs 2,646.92 lakh in Q2FY27, registering a sharp growth of 75.38% QoQ compared to Rs 1,509.23 lakh in Q1FY27 and an increase of 26.60% YoY from Rs 2,090.77 lakh in Q2FY26. Net Profit Attributable to Owners of the Company: Stood at Rs 2,579.06 lakh in Q2FY27, up 77.00% QoQ from Rs 1,457.19 lakh in Q1FY27 and up 32.14% YoY from Rs 1,951.69 lakh in Q2FY26. Total Comprehensive Income: Reported at Rs 2,818.00 lakh in Q2FY27, surging 142.47% QoQ from Rs 1,162.22 lakh in Q1FY27, while decreasing 32.52% YoY compared to Rs 4,176.12 lakh in Q2FY26. Earnings Per Share (EPS): Basic EPS stood at Rs 2.63 per share in Q2FY27, up 77.70% QoQ compared to Rs 1.48 per share in Q1FY27 and up 31.50% YoY from Rs 2.00 per share in Q2FY26. Diluted EPS stood at Rs 2.56 per share in Q2FY27, up 76.55% QoQ from Rs 1.45 per share in Q1FY27 and up 31.96% YoY compared to Rs 1.94 per share in Q2FY26. Standalone Financial Highlights: Revenue from Operations: Stood at Rs 15,858.23 lakh in Q2FY27, an increase of 3.38% QoQ compared to Rs 15,339.14 lakh in Q1FY27 and a growth of 17.50% YoY from Rs 13,496.20 lakh in Q2FY26. Other Income: Reported at Rs 194.71 lakh in Q2FY27, up 38.84% QoQ from Rs 140.24 lakh in Q1FY27 and up 12.73% YoY from Rs 172.72 lakh in Q2FY26. Total Income: Stood at Rs 16,052.94 lakh in Q2FY27, rising 3.71% QoQ compared to Rs 15,479.38 lakh in Q1FY27 and increasing 17.44% YoY compared to Rs 13,668.92 lakh in Q2FY26. Profit Before Tax (PBT): Came in at Rs 1,305.12 lakh in Q2FY27, marginally higher by 0.27% QoQ from Rs 1,301.66 lakh in Q1FY27, but lower by 15.16% YoY compared to Rs 1,538.28 lakh in Q2FY26. Profit After Tax (PAT): Reached Rs 983.05 lakh in Q2FY27, showing a growth of 5.47% QoQ from Rs 932.09 lakh in Q1FY27, and declining 19.46% YoY from Rs 1,220.64 lakh in Q2FY26. Total Comprehensive Income: Stood at Rs 983.05 lakh in Q2FY27, increasing 25.90% QoQ compared to Rs 780.84 lakh in Q1FY27, and declining 32.50% YoY compared to Rs 1,456.39 lakh in Q2FY26. Earnings Per Share (EPS): Basic EPS stood at Rs 1.00 per share in Q2FY27, up 5.26% QoQ from Rs 0.95 per share in Q1FY27, and down 20.63% YoY from Rs 1.26 per share in Q2FY26. Diluted EPS stood at Rs 0.98 per share in Q2FY27, up 5.38% QoQ from Rs 0.93 per share in Q1FY27, and down 19.67% YoY from Rs 1.22 per share in Q2FY26. Business Highlights: Segment Performance: The company and the group operate in a single reportable operating segment, "Cardiovascular Devices" (comprising Balloon Catheter, Cardiac Stents, TAVI, and Occluder), as evaluated by the Chief Operating Decision Maker (CODM) under Ind AS 108. Strategic Investment / Acquisition: Approved an investment by Sahajanand Medical Technologies Ireland Limited (wholly owned subsidiary) to acquire additional stake in SNP Medical Corp., a US-based medical device startup registered in Delaware. SMT Ireland holds a 14.15% stake as of September 30, 2026, and with the proposed acquisition costing up to USD 7,80,000 in cash, its shareholding will increase up to 17.19%. IPO Listing: The company's equity shares were listed on BSE and NSE on October 23, 2026, following the completion of an Initial Public Offering (IPO) of 1,38,22,116 equity shares of face value of Re 1 each at an issue price of Rs 344 per equity share via an offer for sale. Result PDF | |
| 06 Nov 2026 | Sahajanand Medical Technologies Ltd - 545001 - Announcement under Regulation 30 (LODR)-Newspaper Publication | Publication of Unaudited Financial Results for the quarter and half year ended September 30, 2026 in Newspapers. |
Sahajanand Medical Documents
Sahajanand Medical Earnings Call
Sahajanand Medical earnings calls, including management commentary and AI-generated summaries.
Sahajanand Medical Credit Ratings
Sahajanand Medical credit ratings from CRISIL and leading rating agencies, assessing financial stability, investment grade, and related PDF documentation.
| Date | Rating Agency | Company Name | Description | Links |
|---|---|---|---|---|
| 02 Nov 2026 | crisil ratings | Sahajanand Medical Technologies Limited | Sahajanand Medical Technologies Limited:Ratings upgraded to 'Crisil A- / Stable / Crisil A2+ '; rated amount enhanced for Bank Debt | Link |
Sahajanand Medical Investor Presentations
Sahajanand Medical investor presentations, including business updates, financial insights, and strategic initiatives.
| Date | Report Title | Links |
|---|---|---|
| 05 Nov 2026 | Sahajanand Medical Technologies Ltd - 545001 - Announcement under Regulation 30 (LODR)-Investor Presentation |
Sahajanand Medical - Company Profile
Sahajanand Medical Management Structure
Sahajanand Medical management structure with salaries, total experience, and qualifications.
Website: www.smtpl.com
About the company - Business Profile
Sahajanand Medical Technologies was incorporated on September 30, 2001. The company is an R&D-driven; developer of Class III and Class C/D medical devices, focused on Vascular Intervention and Structural Heart solutions. Its portfolio includes coronary stents, balloons, TAVI, occluders, renal stents, and other specialized products
